Canada Life’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Canada Life’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,210	Closed	-$14K	–	2618
2017 Q3	$14K	Sell	1,210 -1	-0.1%	-$11	﹤0.01%	2516
2017 Q2	$12K	Hold	1,211	–	–	﹤0.01%	2529
2017 Q1	$29K	Hold	1,211	–	–	﹤0.01%	2421
2016 Q4	$39K	Hold	1,211	–	–	﹤0.01%	2383
2016 Q3	$60K	Hold	1,211	–	–	﹤0.01%	2293
2016 Q2	$51K	Hold	1,211	–	–	﹤0.01%	2307
2016 Q1	$80K	Hold	1,211	–	–	﹤0.01%	1917
2015 Q4	$75K	Hold	1,211	–	–	﹤0.01%	1960
2015 Q3	$81K	Sell	1,211 -109	-8%	-$8.9K	﹤0.01%	1850
2015 Q2	$129K	Buy	1,320 +109	+9%	+$10.4K	﹤0.01%	1686
2015 Q1	$113K	Buy	1,211 +728	+151%	+$62K	﹤0.01%	1724
2014 Q4	$43K	Hold	483	–	–	﹤0.01%	2152
2014 Q3	$33K	Hold	483	–	–	﹤0.01%	2196
2014 Q2	$28K	Hold	483	–	–	﹤0.01%	2167
2014 Q1	$19K	Hold	483	–	–	﹤0.01%	2145
2013 Q4	$20K	Buy	+483	New	+$14K	﹤0.01%	2133

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Canada Life's MACK Position: Q4 2017 in Review

Canada Life sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 1,210 shares — an estimated $14K sold.

Canada Life first reported a position in MACK in Q4 2013 and held it in 16 quarters. The position peaked at $129K in Q2 2015. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

Canada Life reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Canada Life sold 1,210 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $14K.
Canada Life first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 16 quarters.
Canada Life's Merrimack Pharmaceuticals, Inc. position peaked at $129K in Q2 2015.
78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on Canada Life's 13F filing for Q4 2017, filed 9 Feb 2018.